Drug
Dabrafenib mesylate clinical trials
Also written Tafinlar and GSK2118436B.
A product of Dabrafenib; its studies count on that page too.
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
10 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 10
National Cancer Institute (NCI) (9) · National Human Genome Research Institute (NHGRI) (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1) · Copanlisib hydrochloride (1) · Crizotinib (1)
Studies
Open first, then newest update. How each study uses dabrafenib mesylate is read from its arms, and is right about nine times in ten.
Testing it · 10
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Dabrafenib Mesylate
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02196181Written as Dabrafenib Mesylate
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02224781Written as Dabrafenib Mesylate
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04557956Written as Dabrafenib Mesylate
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03919071Written as Dabrafenib Mesylate
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439292Written as Dabrafenib Mesylate
- Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01947023Written as Dabrafenib Mesylate
- Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01902173Written as Dabrafenib Mesylate
- Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester DiseaseCompletedPhase 2National Human Genome Research Institute (NHGRI)NCT02281760Written as Dabrafenib Mesylate
- Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsWithdrawnPhase 2National Cancer Institute (NCI)NCT03794297Written as Dabrafenib Mesylate
Given in every arm · 1 — dabrafenib mesylate is usual care beside what is tested
Codes
What other systems call dabrafenib mesylate · ClinicalTrials.gg INT016079
- UNII (FDA) B6DC89I63EDABRAFENIB MESYLATEConfirmed FDA, Wikidata
- RxNorm 1425222Confirmed FDA, Wikidata
- Wikidata Q27145089dabrafenib mesylateConfirmed FDA, Wikidata
- NCI Thesaurus C128059Dabrafenib MesylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B6DC89I63E | DABRAFENIB MESYLATE | Confirmed FDA, Wikidata |
| RxNorm | 1425222 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27145089 | dabrafenib mesylate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C128059 | Dabrafenib Mesylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.